New Late-breaking Data from Medtronic Evolut Low Risk Trial

CRT 2024: Evolut TAVR is a safe, effective, and economically cost-effective treatment option for low-risk severe aortic stenosis patients compared to surgery up to four years

Related Keywords

Basel Ramlawi , Corevalve Evolut , Nina Goodheart , Medtronic Evolut , Davidj Cohen , Outcomes Research , Academic Affairs At St , Cardiovascular Research Foundation , Medtronic , Columbia University , Cardiovascular Research Technologies , Lankenau Heart Institute , Cardiothoracic Surgery At Main Line Health System , Evolut Low Risk , Evolut Low Risk Trial , Senior Vice President , Structural Heart , Cardiovascular Portfolio , Low Risk Trial , Academic Affairs , Francis Hospital , Year Outcomes , Contemporary Valves Versus Self Expanding , System Chief , Cardiothoracic Surgery , Main Line Health System , Lankenau Heart ,